Loading
Median Technologies Stock: price and insider trades · France
No insider purchase over the last 90 days. The latest was filed 27 Oct 2025.
Median Technologies: what insiders have been doing
Median Technologies is a Healthcare & Pharma company. Its directors and officers file their transactions with AMF. The last twelve months, up to 18 October 2026, brought 5 filings signed by 4 insiders.
The flow runs one way only: 1 insider bought (1 purchase totalling €24k) and nobody sold on the market. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. At €24k, the purchase published on 27 October 2025 by Nicolas Dano is the largest of the period. Those buying include 1 senior executive.
The last insider purchase was made public on 27 October 2025, 355 days ago. The median gap between a trade and its publication by AMF is 8 days. Under the Market Abuse Regulation, managers have three business days to notify their trades.
Across the 316 companies tracked on its exchange, the median is 6 filings; at 5 filings, this issuer sits below that mark. Over the whole record (from 2021), the tally stands at 15 purchases and 18 sales.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. These figures are compiled from regulatory filings published by AMF. They describe what insiders did and are not a recommendation.
Insider Decl.
60
Thresholds
n/a
Buy Volume
€475,658
15 ops. · all time
Sell Volume
€3M
18 ops. · all time
Who traded when
BuySaleNicolas Dano2 buys5 sales
Fredrik Brag1 buy
Oern Stuge1 buy
Since the insiders bought
- +55.2%Entry €2.90 · Close at T+90 €4.50
- +26.7%Entry €3.13 · Close at T+365 €3.96
- +104.8%Entry €2.30 · Close at T+365 €4.71
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Financial data
as of FY 2025FY ended December 2025 · cache
€4.00
Analyst consensus
3 analysts1.00/5
€10.00Target €11.97(+199%)€14.00
Income statement
Revenue€23.4M
Gross profit€24.1M103% margin
EBITDA-€25.1M-108% margin
Net income-€34.1M-145.2% margin
Valuation
PER (forward)-10.6x
Beta0.59
Balance sheet & cash
Market cap€196.0M
Total debt€21.8M
Free Cash Flow-€18.2M
Profitability & ownership
ROA-33.7%
% insiders26.5%
% institutions11.5%
Last declaration on 2 July 2026
Declarations60 total
50,000 shares@ €1.500.032% mcap100.0% of flowOption d'achatEuronext Growth ParisISIN FR00110498242026DD1124436
84,516 shares@ €1.500.057% mcap4.2% of flowOption d'achatEuronext Growth ParisISIN FR00110498242026DD1123798
12,773 shares@ €1.500.0097% mcap8.7% of flowOption d'achatEuronext Growth ParisISIN FR00110498242026DD1122041
15,000 shares@ €3.20100.0% of flowActionEuronext Growth ParisISIN FR00110498242025DD1068467
7,500 shares@ €3.2010.9% of flowActionEuronext Growth ParisISIN FR00110498242025DD1065529
Canonical exit: 19 Jan 2026 (T+90)
2,000 shares@ €3.192.9% of flowActionEuronext Growth ParisISIN FR00110498242025DD1059415
60,241 shares@ €1.6631.7% of flowActionEuronext Growth ParisISIN FR00110498242025DD1058078
Canonical exit: 3 Nov 2025 (T+90)
4,000 shares@ €2.8455.2% of flowActionEuronext Growth ParisISIN FR00110498242025DD1057596
2,000 shares@ €2.692.4% of flowActionEuronext Growth ParisISIN FR00110498242025DD1053940
2,000 shares@ €2.322.1% of flowActionEuronext Growth ParisISIN FR00110498242025DD1053604
60,242 shares@ €1.6645.5% of flowActionEuronext Growth ParisISIN FR00110498242025DD1053614
Canonical exit: 3 Nov 2025 (T+90)
2,000 shares@ €1.9941.8% of flowActionEuronext Growth ParisISIN FR00110498242025DD1053615
60,241 shares@ €1.663.3% of flowActionEuronext Growth ParisISIN FR00110498242025DD1052971
Canonical exit: 3 Nov 2025 (T+90)
1,000 shares@ €5.87512.7% of flowActionEuronext Growth ParisISIN FR00110498242024DD994378
1,000 shares@ €1.500.7% of flowOption d'achatEuronext Growth ParisISIN FR00110498242024DD994379
1,000 shares@ €5.35752.4% of flowActionEuronext Growth ParisISIN FR00110498242024DD994380
1,000 shares@ €4.96442.3% of flowActionEuronext Growth ParisISIN FR00110498242024DD994372
1,000 shares@ €1.500.7% of flowOption d'achatEuronext Growth ParisISIN FR00110498242024DD994373
1,000 shares@ €6.70723.1% of flowActionEuronext Growth ParisISIN FR00110498242024DD994374
1,000 shares@ €1.500.7% of flowOption d'achatEuronext Growth ParisISIN FR00110498242024DD994375
1,000 shares@ €5.33642.4% of flowActionEuronext Growth ParisISIN FR00110498242024DD994376
1,000 shares@ €1.500.7% of flowOption d'achatEuronext Growth ParisISIN FR00110498242024DD994377
1,000 shares@ €1.500.7% of flowOption d'achatEuronext Growth ParisISIN FR00110498242024DD994369
15,000 shares@ €4.45100.0% of flowActionEuronext ParisISIN FR00110498242023DD942067
Canonical exit: 19 Jan 2024 (T+90)
28,000 shares0ACTIONS GRATUITES AGAEuronext Growth ParisISIN FR00110498242023DD939339
Canonical exit: 22 Jan 2024 (T+90)
25 of 60 declarations
About Median Technologies
Median Technologies is a French healthcare technology company listed on Euronext Growth Paris under ticker ALMDT, ISIN FR0011049824. Founded in 2002 by Fredrik Brag, the company was built around advanced expertise in medical imaging, artificial intelligence and image analysis for oncology. Its market position is that of a medtech/healthtech specialist focused on high-value software and services that help improve early cancer diagnosis and accelerate the development of new treatments. In its recent communications, Median describes itself as a developer of AI-powered medical software for early cancer detection and as a globally leading provider of central imaging services and image analyses for oncology drug developers. The company is also eligible for France’s PEA-PME scheme, which highlights its mid-cap profile and growth-oriented positioning.
Median Technologies’ business is organized around two main pillars. The first is iCRO, an imaging services activity for oncology clinical trials. Through this unit, the company supports biopharmaceutical partners in the design, monitoring and analysis of clinical studies, providing central image reading, data management and advanced imaging analytics. The second pillar is eyonis™, a suite of software as a medical device (SaMD) powered by AI and designed for early cancer detection, with a particular focus on lung cancer screening. This dual model gives Median a combination of recurring services revenue and longer-term software upside, with the potential for improved margins as the SaaS/SaMD platform scales.
Read moreShow less
The company occupies a strategic niche at the intersection of medical imaging, AI and oncology. It targets major unmet medical needs by offering tools that can improve diagnostic accuracy and shorten the timeline for oncology drug development. Its customer base includes large international pharmaceutical companies involved in cancer clinical trials. Median has an international footprint, with commercial and operational activities serving Europe, North America and other major clinical research markets, supported by an organization designed for multi-country programs. Notable features of the company include its proprietary capabilities in computer vision, signal processing and AI applied to medical imaging, as well as its ongoing clinical and regulatory progress around eyonis™.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
